Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival
Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival
Read moreMon, 17th Feb 2020 15:25
Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival
Read more(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that a customer, the Edith Cowan University in Perth, Western Australia, has published results of research into the use of its 'Parsortix' system with melanoma patients.
Read moreAngle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreAngle Eyes US Consent For Parsortix Cancer Medication In Third Quarter
Read moreAngle Gets Study Results Demonstrating Use Of Parsortix In Melanoma
Read moreAngle Submits Positive Test Results For Parsortix System To US FDA
Read more(Sharecast News) - Liquid biopsy company Angle announced on Friday that the Queen Mary University of London (QMUL) European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.
Read moreAngle Notes Queen Mary University's European Cancer Prognosis Patent
Read more(Alliance News) - Angle PLC on Wednesday noted positive results from a study of its Parsortix system in small cell lung cancer.Parsortix is Angle's liquid biopsy technology, meaning it
Read more(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.The study
Read more(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.
Read more(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of
Read more(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.
Read more